KD033 is an anti-PD-L1/IL-15 fusion protein and is the lead molecule from our IL-15 fusion protein platform. KD033 is a novel immunotherapy designed to stimulate innate and adaptive immune responses directed to the tumor microenvironment:

  • IL-15 is an immunostimulatory cytokine that expands key tumor-fighting immune cell types, including natural killer (NK), natural killer T (NKT) and memory T cells without expanding immunosuppressive Treg cells, allowing for robust and durable anti-tumor responses
  • KD033 is designed to direct IL-15 activity to the tumor microenvironment of PD-L1-expressing tumors to achieve a greater therapeutic window

A single dose of KD033 demonstrated robust in vivo pharmacological activity and inhibited tumor growth across multiple syngeneic mouse models.

A Phase 1 clinical trial of KD033, KD033-101, is ongoing in patients with metastatic or locally advanced solid tumors.